Antag Therapeutics has elected Keith Leonard as Chairman of its Board of Directors to support the development of its obesity treatment drug, AT7687. Leonard brings 30 years of biopharmaceutical leadership experience, including roles as CEO and Chairman in various companies. The company is preparing to start Phase 2a clinical trials for AT7687, a novel GIP receptor antagonist designed to improve obesity and cardiometabolic health. Leonard's expertise is expected to guide Antag through this critical growth phase as it aims to offer personalized, effective obesity treatments.
DBV Technologies announced a change in its participation at the 47th Annual Global Healthcare Conference by Goldman Sachs, held on June 9, 2026, in Miami. The company's CEO, Daniel Tassé, will not attend the informal discussion as initially planned d...
Revenium introduced AI Insights, a tool that analyzes enterprise AI usage to pinpoint and rank budget waste, linking each issue to specific transactions for easy fixes. This helps companies recover costs by identifying inefficiencies like outdated mo...
MitoRx Therapeutics has strengthened its leadership team by appointing Alison Strutt as CFO, László Tankó as Consultant CMO, and Sam Fazeli as Non-Executive Director. These hires come as MitoRx prepares to advance its lead drug candidate, MTRX31, a n...
KBR's Mission Technology Solutions secured a $95 million contract to enhance digital engineering and decision support for the U.S. Space Force. The five-year cost-plus-fixed-fee contract aims to accelerate space system development and improve mission...
AmpliTech Group's stock surged nearly 12% in premarket trading following the company's announcement of a significant Open RAN interoperability achievement at the O-RAN ALLIANCE Global PlugFest Spring 2026. The event validated AmpliTech's 64T64R Massi...
